ATLAS-2M, Wk 96 Results: Long-Acting Injectable Cabotegravir + Rilpivirine Every 8 Wks Is Noninferior to Every 4 Wks

Silvia Petretti on individualizing antiretroviral therapy according to patient factors from Clinical Care Options

Silvia Petretti Released: October 22, 2021

Clinical Care Options (CCO) expert analysis of new HIV data from IDWeek 2021, provided by expert HIV faculty

Eric S. Daar, MD Released: October 21, 2021

Expert selections of important HIV data from IDWeek 2021, including current and investigational ART, HIV PrEP, and metabolic outcomes of ART.

Eric S. Daar, MD Darcy Wooten, MD Released: October 19, 2021

Switch to DTG/3TC shows high levels of efficacy, favorable safety and tolerability, and high barrier to resistance through 3 years from IDWeek 2021 presented by Clinical Care Options (CCO)